Xolegel Wins FDA Approval For Treatment Of Seborrheic Dermatitis

Barrier Therapeutics' treatment for seborrheic dermatitis has been approved by the U.S. Food and Drug Administration, the company said in a statement.
Xolegel (2% ketoconazole, USP) is a once-daily topical gel to treat the skin condition, characterized by a red, scaly, itchy rash that primarily develops on the face, scalp, hairline, eyebrows and trunk.
Seborrheic dermatitis affects 3 percent to 5 percent of the U.S. population, or about 8.5 million people, the company said. The condition often recurs, requiring additional treatment.